THE DEVELOPMENT OF INDUSTRY STANDARD SAMPLE QUALIFICATION PROCEDURE OF RECOMBINANT ACTIVATED BLOOD CLOTTING FACTOR VII FOR PROVING OF IDENTITY BY PEPTIDE MAPPING METHOD

Introduction. The use of European reference standard with the known structure (СRS Нuman coagulation factor) as a reference allows to confirm identity of the primary structure of new batches of the recombinant protein. Manufactures normally use an industry standard sample due to the high cost of the European reference standard and to make sure that national samples are independent from the international reference standards. Regulatory requirements for the qualification procedure of an industry standard sample are absent.

Materials and methods. Batch of recombinant activated clotting factor VII (rFVIIa) (Eptacog alpha) («Koagil») was selected as a candidate material. The method of strong hydrolysis with the initial deglycosylation of the molecule was used. Amino acid sequence of rFVIIa, described in the monograph 01/2015:2534 of European Pharmacopoeia (Ed. 9.0) was used as a reference. Peptide mapping and mass-spectrometric assay were used in the study.

Results. Qualification procedure of industry standard sample of rFVIIa was developed. The standard sample was used for the proof of identity of rFVIIa by RP-HPLC peptide mapping. Qualification procedure of an industry standard sample of rFVIIa allows to obtain fully characterized reference sample with the established structure. The use of this standard sample guarantees accurate assessment of the identification by peptide mapping of the new batches of rFVIIa with or without European reference standard.

Conclusion. Peptide mapping and mass-spectrometric assay allows us to confirm amino acid sequence of light and heavy chains of rFVIIa with 100 % coverage. The peptide map was established for the candidate material in comparison with the original drug NovoSeven and the selection of сharacteristic peaks was justified. These peaks were characterized by stability and symmetry factors. Amino acid sequence of peptides corresponding to the reference peaks and their primary localization in the molecule were established by the use of tandem mass-spectrometry.

Conflict of interest. The authors Smolov M. А., Shukurov R. R., Vishnevskiy A. Yu. are the employees of the International Biotechnology Center «Generium».

1. Инструкция по применению препарата «Коагил II» производства АО «Генериум», Россия [электронный ресурс]. http://www.generium.ru/upload/ preparations/manual/%D0%98%D0%BD%D1%81%D1%82%D1%80%D1%83% D0%BA%D1%86%D0%B8%D1%8F_%D0%9A%D0%BE%D0%B0%D0%B3%D0% B8%D0%BB_VII.pdf (дата обращения: 18.01.18).

2. Лекарственные средства, получаемые методами рекомбинантных ДНК: ОФС.1.7.1.0007.15. Государственная фармакопея Российской Федерации. XIII издание. Том II [Электронный ресурс]. http://193.232.7.120/feml/clinical_ref/ pharmacopoeia_2/HTML/#520 (дата обращения: 09.02.2018).

3. Фадейкина ОВ, Волкова РА. Разработка порядка аттестации стандартных образцов биологических лекарственных средств. Химико-фармацевтический журнал. 2017;8:80—6.

4. Меркулов ВА, Саканян ЕИ, Волкова РА, Климов ВИ, Шемерянкина ТБ, Яшкир ВА. Фармакопейные стандартные образцы и практика их применения в отечественной системе стандартизации лекарственных средств. Химико-фармацевтический журнал. 2016;50:258—61.

5. Волкова РА, Фадейкина ОВ, Климов ВИ и др. Актуальные вопросы стандартных образцов в сфере обращения биологических лекарственных средств. БИОпрепараты. 2016;16:229—36.

6. Устинникова ОБ, Новикова ЕВ, Рунова ОБ, Шведов ДВ, Жиляева МВ. Гармонизация требований оценки активности рекомбинантного фактора свертывания крови. Химико-фармацевтический журнал. 2017;51:54—7.

7. Хроматография: ОФС.1.2.1.2.0001.15. Государственная фармакопея Российской Федерации. XIII издание. Том I [Электронный ресурс]. http://193.232.7.120/ feml/clinical_ref/pharmacopoeia_1/HTML/#446 (дата обращения: 18.01.18).

8. Остальные источники см. в References.

9. References

10. Human coagulation factor VIIа (rDNA) concentrated solution 01/2015:2534. Available at: http://online.edqm.eu/EN/entry.htm (accessed 05.11.2017).

11. Instructions for use of the drug «Coagil VII», Generium, Russia. Available at: http://www.generium.ru/upload/preparations/manual/%D0%98%D0%BD%D1%8 1%D1%82%D1%80%D1%83%D0%BA%D1%86%D0%B8%D1%8F_%D0%9A%D0% BE%D0%B0%D0%B3%D0%B8%D0%BB_VII.pdf (accessed 18.01.18) (in Russian).

12. Russia State Pharmacopeia XIII. GPM. 1.7.1.0007.15. Drugs obtained by recombinant DNA. Available at: http://193.232.7.120/feml/clinical_ref/ pharmacopoeia_2/HTML/#520 (accessed 09.02.2018) (in Russian).

13. Biotechnology-derived articles (1045). Available at: http://www.drugfuture. com/Pharmacopoeia/USP32/pub/data/v32270/usp32nf27s0_c1045.html (accessed 09.02.2018).

14. ICH Q5В Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of R-DNA Derived Protein Products. International Conference on Harmonisation. Available at: http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5B/Step4/ Q5B_Guideline.pdf (accessed 23.01.2018).

15. Рeptide mapping 2.2.55. Available at: http://online.edqm.eu/EN/entry.htm (accessed 05.11.2017). 7. Fadeikina OV, Volkova RA. Elaboration of certification procedures for reference standards of biological drugs. Pharmaceutical Chemistry Journal (KhimikoFarmatsevticheskii Zhurnal). 2017;51:44—50 (in Russian).

16. Terms and definitions used in connection with reference material. ISO Guide 30:1992 (released: 30:2015). Available at: http://www.iso.org/iso/catalogue_ detail. htm?csnumber=21638 (accessed 19.09.2017).

17. Merkulov VA, Sakanyan EI, Volkova RA, Klimov VI, Shemeryankina TB, Yashkir VA. Pharmacopeia standart samples and their practical application in the national drug standardization system. Pharmaceutical Chemical Journal (KhimikoFarmatsevticheskii Zhurnal). 2016;50:258—61 (in Russian).

18. Reference material — General and statistical principles for certification. ISOGuide 35:2006. Available at: http://www.iso.org/iso/catalogue_detail. htm?csnumber (accessed 19.09.2017).

19. Volkova RA, Fadeikina OV, Klimov VI et al. Topical issues related to reference standards in the sphere of circulation of biological products. BIOpreparations. Prevention, Diagnosis, Treatmen (Biopreparaty). 2016;16:229—36 (in Russian).

20. WHО. Recommendations for the preparation, characterization and establishment of international and other biological reference standards. WHO Technical Report Series. 2006;932, annex 2. Available at: http://www.who.int/bloodproducts/publications/ TRS932Annex2_Inter_biolefstandardsrev2004.pdf (accessed 19.09.2017).

21. General requirements for the competence of reference material producers. ISO Guide 34:2009 (ISO 17034:2016). Available at: http://www.iso.org/iso/ catalogue_detail.htm?csnumber=50174 (accessed 19.09.2017).

22. Ustinnikova OB, Novikova EV, Rounova OB, Shvedov DV, Zhilyaeva MV. Harmonization of requirements for determination of the recombinant blood clotting factor (rFVIIa) activity. Pharmaceutical Chemical Journal (Khimiko-Farmatsevticheskii Zhurnal). 2017;51:54—7 (in Russian).

23. Russia State Pharmacopeia XIII. GPM.1.2.1.2.0001.15 Chromatography. Available at: http://193.232.7.120/feml/clinical_ref/pharmacopoeia_1/HTML/ #446 (accessed 18.01.18) (in Russian).

24. ICH Q2B Validation of analytical procedures: Text and Methodology. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Quality/Q2B//.pdf (accessed 06.11.2017).